3 small-cap ASX shares with over 30% upside: brokers

These three small market cap shares have more than a 30% upside according to brokers.

Australian Vintage Ltd (ASX: AVG), Clarity Pharmaceuticals Ltd (ASX: CU6) and AIC Mines Ltd (A1M) are rated as buy or overweight in separate reports published by the ASX.

Let’s take a look at these three ASX shares in more detail.

AIC Mines

AIC Mines shares are flat today and currently fetching 45 cents. Ord Minnett has placed a “speculative buy” rating on the AIC Mines share price with an 80 cent price target. This implies an almost 78% upside on the current share price.

Ord Minnett is positive on AIC Mines’ takeover of Demetallica Limited (ASX: DRM). Commenting on the acquisition, analysts said:

….the acquisition increases A1M’s prominence in terms of scale, liquidity, mine life and risk profile – which should place it on the radar for more investors. We increase our target price to A$0.80/sh (+7%) and retain our positive view.

Australian Vintage

Australian Vintage shares are down 3.2% today and are currently fetching 60.5 cents. MA Moelis Australia has placed a buy rating on the wine company’s share price with an 87 cent price target. This implies an upside of about 43%. Analysts are positive on the company’s agreement to sell multiple commercial vineyards to Warakirri Asset Management for $62.5 million. This deal “unlocks significant value” from the company’s balance sheet, CEO Craig Garvin said earlier this month.

Commenting on the outlook for Australian Vintage, broker MA Moelis Australia said:

We see the sale and leaseback of the Coldridge and Grande Junction commercial
vineyards as a positive move, which strengthens the balance sheet at a time when
market conditions are relatively challenging due to an oversupply of Australian wine.

We maintain our buy rating and raise our target price to $0.87 (prev: $0.81),
reflecting the change in capital structure.

Clarity Pharmaceuticals

Clarity Pharmaceuticals shares are 1.1% in the green today and are currently priced at 92 cents. Wilsons has maintained an “overweight” rating on Clarity Pharmaceuticals with a 12-month price target of $1.22. This implies a nearly 33% upside based on the current share price.

Wilsons is positive on Clarity’s upcoming trial results for its SAR-bisPSMA product for prostate cancer. Analysts said:

We maintain our overweight rating on Clarity Pharmaceuticals with a revised price target of $1.22/sh. We view the upcoming release of Clarity’s Phase I/II propeller trial results for their 64Cu-SAR-bisPSMA in prostate cancer diagnosis as a de-risking event, with clear signals
towards a positive outcome.

Pending the release of these results, we revise our SOTP ROVs, additionally supported by the SAR-Bombesin PSMA-negative prostate tracking ~3 years ahead of schedule.

The post 3 small-cap ASX shares with over 30% upside: brokers appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why is the Woodside share price smashing the ASX 200 on Monday?
• Why is the Origin Energy share price dumping 8% on Monday?
• Will the Flight Centre share price have a better year in 2023?
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Why is the Woolworths share price lagging the ASX 200 on Monday?

Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/PAwmLSn